Evidence map›Paper›PMID 26418697›Full record

ArticleAnesthesiology2015

Comparative Effectiveness of Calabadion and Sugammadex to Reverse Non-depolarizing Neuromuscular-blocking Agents.

Friederike Haerter, Jeroen Cedric Peter Simons, Urs Foerster, Ingrid Moreno Duarte, Daniel Diaz-Gil, Shweta Ganapati, Katharina Eikermann-Haerter, Cenk Ayata, Ben Zhang, Manfred Blobner and 2 more

Open access · greenAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Anesthesiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
9.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 89 citations in OpenAlex.

  1. Trial
  2. Article
  3. Acyclic cucurbituril as sequestrant for acetaminophen.Chemical communications (Cambridge, England) · 2026
    Article
  4. Narrative Review of the Role of Nondepolarizing Neuromuscular Blocking Agents in Anesthesia: Perspective 2026.Medical science monitor : international medical journal of experimental and clinical research · 2026
    Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Acyclic cucurbit[Beilstein journal of organic chemistry · 2025
    Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. In Vitro and In Vivo Sequestration of Phencyclidine by MeChemistry (Weinheim an der Bergstrasse, Germany) · 2021
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Friederike HaerterFrom the Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts (F.H., J.C.P.S., I.M.D., D.D.-G., M.E.); Clinic of Anesthesiology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany (U.F., M.B.); Department of Chemistry and Biochemistry, University of Maryland, College Park, Maryland (S.G., B.Z., L.I.); Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts (K.E.-H., C.A.); and Department of Anesthesia and Critical Care Medicine, University Hospital Essen, University Duisburg-Essen, Essen, Germany (M.E.).
Jeroen Cedric Peter Simons
Urs Foerster
Ingrid Moreno Duarte
Daniel Diaz-Gil
Shweta Ganapati
Katharina Eikermann-Haerter
Cenk Ayata
Ben Zhang
Manfred Blobner
Lyle Isaacs
Matthias Eikermann
Massachusetts General Hospital · USUniversity of Maryland, College Park · USZero to Three · USKlinikum rechts der Isar · DE

Funding

Acyclic Cucurbit n uril Molecular Containers for Drug Solubilization and DeliveryR01CA168365 · NCI · UNIV OF MARYLAND, COLLEGE PARK · PI BRIKEN, VOLKER, ISAACS, LYLE D · 2013 to 2017
$1.9M
NCI NIH HHS CA-168365NCI NIH HHS R01 CA168365
6 · The paper itself

Abstract

backgroundThe authors evaluated the comparative effectiveness of calabadion 2 to reverse non-depolarizing neuromuscular-blocking agents (NMBAs) by binding and inactivation.

methodsThe dose-response relationship of drugs to reverse vecuronium-, rocuronium-, and cisatracurium-induced neuromuscular block (NMB) was evaluated in vitro (competition binding assays and urine analysis), ex vivo (n = 34; phrenic nerve hemidiaphragm preparation), and in vivo (n = 108; quadriceps femoris muscle of the rat). Cumulative dose-response curves of calabadions, neostigmine, or sugammadex were created ex vivo at a steady-state deep NMB. In living rats, the authors studied the dose-response relationship of the test drugs to reverse deep block under physiologic conditions, and they measured the amount of calabadion 2 excreted in the urine.

resultsIn vitro experiments showed that calabadion 2 binds rocuronium with 89 times the affinity of sugammadex (Ka = 3.4 × 10 M and Ka = 3.8 × 10 M-). The results of urine analysis (proton nuclear magnetic resonance), competition binding assays, and ex vivo study obtained in the absence of metabolic deactivation are in accordance with an 1:1 binding ratio of sugammadex and calabadion 2 toward rocuronium. In living rats, calabadion 2 dose-dependently and rapidly reversed all NMBAs tested. The molar potency of calabadion 2 to reverse vecuronium and rocuronium was higher compared with that of sugammadex. Calabadion 2 was eliminated renally and did not affect blood pressure or heart rate.

conclusionsCalabadion 2 reverses NMB induced by benzylisoquinolines and steroidal NMBAs in rats more effectively, i.e., faster than sugammadex. Calabadion 2 is eliminated in the urine and well tolerated in rats.

Indexed as

AndrostanolsAnimalsAtracuriumDose-Response Relationship, Druggamma-CyclodextrinsHeterocyclic Compounds, 4 or More RingsMaleNeostigmineNeuromuscular Nondepolarizing AgentsRatsRocuroniumSugammadexSulfonic AcidsVecuronium BromideAndrostanolsAtracuriumcalabadion 1cisatracuriumgamma-CyclodextrinsHeterocyclic Compounds, 4 or More RingsNeostigmineNeuromuscular Nondepolarizing AgentsRocuroniumSugammadexSulfonic AcidsVecuronium Bromide

Identifiers

PMID26418697
PMCPMC4679413
OpenAlexW2190830215

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.